IN-VITRO TESTING OF DRY POWDER INHALERS

被引:20
作者
VANOORT, M
机构
[1] Glaxo Research Institute, Inhalation Product Development, Research Triangle Park, NC, 27709
关键词
D O I
10.1080/02786829408959754
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
There is increasing focus on the development of dry powder inhalers (DPIs) for the delivery of therapeutic entities to the lungs. In vitro testing of metered-dose inhalers (MDIs) has evolved through the years and general tests and methods have been published through USP general chapter [601], monographs, and guidelines issued by the FDA. In contrast, very few guidelines have been established for the testing of dry powder inhaler systems. In fact, these systems may prove to be more difficult to propose general tests for because they are based on different principles leading to a greater diversity in the number of types of devices and formulations in comparison to the MDIs. To form absolute standards at this stage will be difficult and this paper will present a comparison of the in vitro test methods of MDIs to some of the DPIs that are commercially available and suggests some guidelines to follow.
引用
收藏
页码:364 / 373
页数:10
相关论文
共 13 条
[1]   THE RELATIONSHIP BETWEEN POWDER INHALER RESISTANCE AND PEAK INSPIRATORY CONDITIONS IN HEALTHY-VOLUNTEERS - IMPLICATIONS FOR IN-VITRO TESTING [J].
CLARK, AR ;
HOLLINGWORTH, AM .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1993, 6 (02) :99-110
[2]  
ENGEL T, 1990, EUR RESPIR J, V3, P1037
[3]  
JAEGFELDT H, 1987, NEW CONCEPT INHALATI, P90
[4]   DELIVERY CHARACTERISTICS OF ALBUTEROL POWDER AEROSOL BY ROTAHALER [J].
KIM, CS ;
GARCIA, L .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1993, 6 (03) :199-211
[5]  
MASON EB, 1983, HUMAN PHYSL, P385
[6]  
MEAKIN BJ, 1993, AM REV RESPIR DIS, V147, pA997
[7]  
MEAKIN BJ, 1993, ALA ATA INT C SAN FR
[8]   TERBUTALINE SULFATE TURBUHALER - EFFECT OF INHALED FLOW-RATE ON DRUG DEPOSITION AND EFFICACY [J].
NEWMAN, SP ;
MOREN, F ;
TROFAST, E ;
TALAEE, N ;
CLARKE, SW .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 74 (2-3) :209-213
[9]  
Spiro S.G., 1992, BR J CLIN RES, V3, P115
[10]  
Sumby B, 1992, BR J CLIN RES, V3, P117